Summit Therapeutics Inc. (SMMT)
NasdaqGM · Price as of · Nasdaq Real Time Price
- Analysts13
- Implied upside+117.7%
- Target range$9.91 to $42.05
- EPS expected-$0.22
- A year ago-$0.23
- Revenue expected$53,640
- Estimate range-$0.31 to -$0.14
SEC filings
| Form | Filed | Description |
|---|---|---|
| 8-K | August 5, 2026 | 8-K |
| 8-K | July 23, 2026 | 8-K |
| 424B5 | July 23, 2026 | 424B5 |
| 10-Q | July 23, 2026 | 10-Q |
| 8-K | July 23, 2026 | 8-K |
| 8-K | July 22, 2026 | 8-K |
| 8-K | June 12, 2026 | 8-K |
| 4 | June 12, 2026 | FORM 4 |
Frequently asked questions
When does SMMT report earnings?
Summit Therapeutics Inc. (SMMT) is scheduled to report quarterly results on October 19, 2026 (estimated). The 12-analyst consensus is -$0.22 per share on revenue of $53,640 for the quarter ending September 30, 2026, against -$0.23 and $0.00 a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for SMMT?
13 analysts cover Summit Therapeutics Inc. (SMMT). The consensus rating is Buy. The average price target is $28.65, in a range of $9.91 to $42.05.
Are insiders buying or selling SMMT?
We have no qualifying Form 4 insider purchases or sales on record for Summit Therapeutics Inc. (SMMT). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see SMMT SEC filings?
Recent filings are listed on this page, newest first. The latest is an 8-K filed August 5, 2026.